Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Consumer Healthcare Looks to Stable, Sustainable Growth: President
June 13, 2017
- PeptiDream Licenses Peptide Discovery Platform to Shionogi
June 13, 2017
- Mochida, Ayumi Hook Up on Sales of Enbrel, Humira Biosimilars
June 13, 2017
- Kissei Gets Japan Rights to Avacopan for Rare Kidney Diseases
June 12, 2017
- Lurasidone Beats Primary Endpoint in Bipolar I Depression: Sumitomo Dainippon
June 12, 2017
- Astellas/Pfizer Amend Xtandi Trial Protocol, Topline Data Due Out This Year
June 12, 2017
- Alcohol Dependence Med Nalmefene Delivers Positive Japan Data: Otsuka/Lundbeck
June 9, 2017
- Pediatric Ozex Generics of Takata, Meiji Now Have Same Indications as Originator
June 8, 2017
- 3 Japan Generic Majors See Decelerating Growth in FY2016: Jiho Tally
June 8, 2017
- FDA Accepts Sawai’s ANDA for Tecfidera Generic
June 8, 2017
- Daiichi Sankyo’s DS-8201 Yields 40.2% ORR in HER2-Expressing Solid Tumors: PI
June 7, 2017
- CSL Japan Chief Anticipates Annual Sales of 40 Billion Yen in Midterm Business Plan Achievable
June 7, 2017
- Pfizer Boosting Global Oncology Footprint with Diverse Portfolio: SVP
June 7, 2017
- PII Data Updated for Sumitomo Dainippon’s Napabucasin
June 6, 2017
- Details Revealed for Lenvima’s Non-Inferiority Study vs Nexavar in 1st Line HCC
June 6, 2017
- Linzess Most Heavily Promoted for GPs in Launch Month of March: Anterio
June 6, 2017
- Discontinuation of Development Continues for Novel Diabetes Drugs, Including Daiichi Sankyo’s GPR119 Agonist
June 6, 2017
- Astellas, Kyoto Univ. Launch New 3-Year Joint Project
June 5, 2017
- AbbVie to Seek Indication Expansions for Humira, Competing with Biosimilars on the Strength of Original Product’s Reliability
June 5, 2017
- Sugino Appointed President of Amgen Astellas
June 2, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…